Papa P, Rocchi L, Mainardi C, Donzelli G
Legal Medicine and Toxicology Service S. Matteo Hospital, Pavia, Italy.
Eur J Clin Chem Clin Biochem. 1997 May;35(5):369-70.
The interference of buflomedil with the monoclonal and polyclonal EMIT d.a.u. amphetamine immunoassays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false positive results with the monoclonal EMIT d.a.u. assay, as did urine specimens collected 2 hours after the first oral dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d.a.u. amphetamine assay. Urine samples with buflomedil added at concentrations greater than 100 mg/l gave false positive results with the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56-400 mg/l) failed to correlate to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged drug, probably interfere in the monoclonal EMIT d.a.u. assay.
研究了丁咯地尔对单克隆和多克隆EMIT d.a.u. 苯丙胺免疫测定的干扰情况。从20名每日服用600毫克丁咯地尔的患者收集的尿液样本，用单克隆EMIT d.a.u. 测定法得出假阳性结果，首次口服丁咯地尔2小时后收集的尿液标本也是如此。相反，多克隆EMIT d.a.u. 苯丙胺测定法未出现假阳性结果。添加浓度大于100毫克/升丁咯地尔的尿液样本，用单克隆免疫测定法得出假阳性结果。在患者尿液中发现的丁咯地尔浓度（56 - 400毫克/升）与EMIT测定反应无关：该结果表明，除了未改变的药物外，一种或多种丁咯地尔代谢物可能干扰单克隆EMIT d.a.u. 测定法。
